A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)

NCT06674148 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

124

Enrollment

OTHER

Sponsor class

Conditions

Interstitial Lung Disease
Qifangfeixian Granules

Interventions

DRUG: Qifangfeixian granules
OTHER: Placebo

Sponsor

Huilan Zhang